Target intelligence / Profile preview

Heat shock protein family B (small) member 7 (HSPB7)

Target
HSPB7
Molecular classification
Small heat shock protein, Molecular chaperone, Other
01

Overview

Heat shock protein family B (small) member 7 (HSPB7) is a muscle-specific molecular chaperone, predominantly expressed in the heart, belonging to the small heat shock protein family. Functionally, HSPB7 stabilizes sarcomeric structure and organizes actin filaments, modulates protein homeostasis, and has both chaperone and redox regulatory activity. It prevents aggregation of large cytoskeletal proteins (e.g., filamin C, titin) and plays a central role in maintaining cardiovascular integrity. Genetic mutations or deficiency in HSPB7 lead to severe cardiac defects, arrhythmias, and heart failure, and the protein is often inactivated or lost in diverse cancers, where it can act as a tumor suppressor. HSPB7 is also under investigation as a potential biomarker of cardiac disease and injury. There are currently no known direct-acting pharmacological inhibitors or modulators of HSPB7.

Other names
heat shock protein beta-7cvHSPCardiovascular heat shock proteinHspB7heat shock 27kD protein family, member 7 (cardiovascular)heat shock 27kDa protein family, member 7 (cardiovascular)HSPB7Hsp25-2
02

Mechanism of action

No pharmacological drugs are currently known to target HSPB7 directly; its mechanisms relate to chaperone activity and actin regulation. Mechanistic studies refer to genetic manipulation or modulation of protein activity rather than drug action.

03

Biological functions

Chaperone activity (protein folding, prevention of protein aggregation)Sarcomere organization and stabilizationRegulation of cytoskeleton assembly (actin binding/modulation)Redox regulation (reactive electrophilic species sensor)Maintenance of cardiac proteostasis and function
04

Disease associations

Cardiovascular disease (cardiomyopathy, heart failure, cardiac conduction system defects)Cancer (tumor suppressor function, frequently inactivated in malignancies)Other (potential role in neurodegenerative disease due to suppression of polyglutamine aggregation)
05

Safety considerations

Cardiac toxicity if HSPB7 is inhibited or genetically deleted, leading to sarcomere disruption, cardiac arrhythmia, or embryonic lethalityPotential impact on tumor biology if modulated inappropriately
06

Biomarkers

Cardiac injury/ischemia markerCardiomyopathy biomarkerCancer biomarker (tumor suppressor loss)

Beyond the preview

Go deeper on Heat shock protein family B (small) member 7 (HSPB7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heat shock protein family B (small) member 7 (HSPB7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call